Fri, Mar 6, 2015, 7:58 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

medxwatcher 3 posts  |  Last Activity: Feb 8, 2015 10:50 AM Member since: Oct 10, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • medxwatcher medxwatcher Feb 8, 2015 10:50 AM Flag

    On the contrary, Alopecia Areata is a relatively common autoimmune condition that affects six million people in the US alone. Both ruxo and tofa are being studied in this condition. Present treatment is with steroids and there is no cure.

    Sentiment: Buy

  • medxwatcher by medxwatcher Jan 12, 2015 12:14 PM Flag

    I had trouble, on and off, with the feed but what I caught was mind boggling in a good way. The breadth of the Incyte pipeline is impressive and I'm glad to see that Incyte is being so aggressive in adding a new platform in its drug discovery process that will enable us to produce the fully human antibodies acting as checkpoint inhibitors for future clinicals in combination with 360. Nice to see that the 360 IDO1 inhibitor has a name, epocadostat, or something akin to that. There should be an abundance of activity this coming year!

    Sentiment: Buy

  • Reply to

    Arthritis Drug

    by whc60805 Dec 9, 2014 9:01 AM
    medxwatcher medxwatcher Dec 9, 2014 3:42 PM Flag

    The Roche-Chugai drug, Actemra(tocilizumab), is an IL-6 inhibitor and that is probably one of the drugs being referred to in this press release. All indications are that it has many more side effects than bari. We'll see, I'm certainly optimistic about the success of bari.

    Sentiment: Buy

90.00-1.97(-2.14%)Mar 6 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.